ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Feb 23rd, 2021 - Anaplastic large cell lymphoma (ALCL), ALK negative (ALK-) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK- has to be differentiat...

Feb 22nd, 2021 - The management of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) has been well established. However, there is minimal data and significant variability in the management of asymptomatic textured implant (ATI) patients. The purp...

Feb 11th, 2021 - We hypothesized that murine double minute X (MDMX), a negative p53-regulator, may be involved in dysfunctional p53-signaling in anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive and ALK-negative, characterized freque...

Feb 9th, 2021 - Late seroma related to breast silicone implants is a rare complication. Interest for its characterization has grown after its association with the recently described breast implant-associated anaplastic large cell lymphoma. The differential diagno...

Feb 9th, 2021 - Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with...

Feb 11th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

Feb 5th, 2019 - The Food and Drug Administration (FDA) wants to increase awareness about an association between all breast implants, regardless of filling or texture, and Breast Implant Associated- Anaplastic Large Cell Lymphoma (BIA-ALCL). The FDA received repor...

Jan 30th, 2019 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that ari...

Jan 30th, 2019 - National Comprehensive Cancer Network (NCCN) guidelines represent the consensus standard of care for diagnosis and management of the majority of known cancers. NCCN guidelines on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) ...

Feb 11th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

Feb 23rd, 2021 - Anaplastic large cell lymphoma (ALCL), ALK negative (ALK-) is an aggressive lymphoproliferative disorder of mature T lymphocytes characterised by hallmark cells, CD30 positivity and lacking ALK protein expression. ALCL, ALK- has to be differentiat...

Feb 22nd, 2021 - The management of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL) has been well established. However, there is minimal data and significant variability in the management of asymptomatic textured implant (ATI) patients. The purp...

Feb 11th, 2021 - We hypothesized that murine double minute X (MDMX), a negative p53-regulator, may be involved in dysfunctional p53-signaling in anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK)-positive and ALK-negative, characterized freque...

Feb 9th, 2021 - Late seroma related to breast silicone implants is a rare complication. Interest for its characterization has grown after its association with the recently described breast implant-associated anaplastic large cell lymphoma. The differential diagno...

Feb 9th, 2021 - Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with...

Jul 9th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 9th, 2020 - The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending brentuximab vedotin (Adcetris, Takeda) with cyclophosphamide, doxorubicin, and prednisone (CHP) for untreated systemic anaplastic large ce...

Jul 8th, 2020 - As of April 2020, there have been 68 cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) reported in the UK. This figure includes cases where the original implantation did not occur in the UK. Based on the number of cases,...

The information in this letter has been superseded by The FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from the Market: FDA Sa...

Aug 21st, 2019 - Health professionals have been reminded to continue to report suspected cases of breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) in patients who have had breast implants or who have had them removed. In an update to two previou...